Abstract
Positive estrogen and progesterone receptors (ER, PR) breast cancers (BC) require endocrine therapy and were associated to favorable outcomes. Hormone receptors (HR) status is considered a crucial predictive factor. The ER−PR+ group is reported to be only 1–5% of all BCs and remains poorly understood and was associated to poor outcomes The aim of this study was to compare the clinical outcomes of patients with single HR positive BC to those with ER+PR+ tumors and TNBC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
